Citations 4
Correction: American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity
Jirapinyo, Pichamol , Hadefi, Alia , Huberty, Vincent, Sullivan, Shelby , Thompson, Christopher C. , Patai, Árpád V. , Pannala, Rahul , Goelder, Stefan, Kushnir, Vladimir , Apovian, Caroline M., Chapman, Christopher G., Davidson, Paul , Kumbhari, Vivek , Esker, Janelle, Hucl, Tomáš , Schulman, Allison R. , Zelber‐Sagi, Shira , Bain, Paul , Huberty, Vincent, Barthet, Marc , Boškoski, Ivo , Donatelli, Gianfranco , Hayee, Bu , Pryor, Aurora Dawn , Maselli, Roberta , Pattou, François , Durieux, Valérie , Τriantafyllou, Κonstantinos , Thosani, Nirav C
Endoscopy | July 28, 2025 | Volume: 57 | Issue: 09 | Pages: C12-C12
American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity
Jirapinyo, Pichamol , Hadefi, Alia , Sullivan, Shelby , Thompson, Christopher C. , Patai, Árpád V. , Pannala, Rahul , Goelder, Stefan, Kushnir, Vladimir , Apovian, Caroline M., Chapman, Christopher G., Davidson, Paul , Kumbhari, Vivek , Esker, Janelle, Hucl, Tomáš , Schulman, Allison R. , Zelber‐Sagi, Shira , Bain, Paul , Huberty, Vincent , Barthet, Marc , Boškoski, Ivo , Donatelli, Gianfranco , Hayee, Bu , Pryor, Aurora Dawn , Maselli, Roberta , Pattou, François , Durieux, Valérie , Τriantafyllou, Κonstantinos , Thosani, Nirav C
Endoscopy | April 19, 2024 | Volume: 56 | Issue: 06 | Pages: 437-456
AbstractThis joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ≥30 kg/m2, or with a BMI of 27.0–29.9 kg/m2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.
Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop
Rickels, Michael R. , Stock, Peter G. , Koning, Eelco J.P. de , Piemonti, Lorenzo , Pratschke, Johann , Alejandro, Rodolfo , Berney, Thierry , Choudhary, Pratik , Johnson, Paul , Kandaswamy, Raja , Kay, Thomas W. H. , Keymeulen, Bart , Kudva, Yogish C. , Latres, Esther , Langer, R.M. , Lehmann, Roger , Ludwig, Barbara , Markmann, James F. , Marinac, Marjana , Senior, Peter , Shaw, James , White, Steven , Berney, Thierry , Rickels, Michael R , Choudhary, Pratik , De Koning, Eelco J P , Bellin, Melena D. , Odorico, Jon S. , Pattou, François , Vantyghem, Marie‐Christine
Transplant International | February 17, 2018 | Volume: 31 | Issue: 4 | Pages: 343-352
Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010
Barton, Franca B. , Rickels, Michael R. , Alejandro, Rodolfo , Hering, Bernhard J. , Wease, Stephen, Oberholzer, José , Garfinkel, Marc R., Levy, Marlon F. , Pattou, François , Berney, Thierry , Secchi, Antonio , Messinger, Shari , Senior, Peter , Maffi, Paola , Posselt, Andrew M., Stock, Peter G. , Luo, Xunrong , Kandeel, Fouad , Cagliero, Enrico, Turgeon, Nicole A. , Naji, Ali , Greenbaum, Carla J. , Kudva, Yogish C. , Brayman, Kenneth L. , Aull, Meredith J. , Kay, Tom, Fernandez, Luis A. , Vantyghem, Marie‐Christine , Naziruddin, Bashoo , Odorico, Jon S. , Kaufman, Dixon B. , Witkowski, Piotr , O’Connell, Philip J. , Larsen, Christian P. , Bellin, Melena D. , Shapiro, A. M. James , Berney, Thierry , Rickels, Michael R , Messinger, Shari , Pattou, F
Diabetes Care | June 22, 2012 | Volume: 35 | Issue: 7 | Pages: 1436-1445
OBJECTIVE To describe trends of primary efficacy and safety outcomes of islet transplantation in type 1 diabetes recipients with severe hypoglycemia from the Collaborative Islet Transplant Registry (CITR) from 1999 to 2010. RESEARCH DESIGN AND METHODS A total of 677 islet transplant-alone or islet-after-kidney recipients with type 1 diabetes in the CITR were analyzed for five primary efficacy outcomes and overall safety to identify any differences by early (1999–2002), mid (2003–2006), or recent (2007–2010) transplant era based on annual follow-up to 5 years. RESULTS Insulin independence at 3 years after transplant improved from 27% in the early era (1999–2002, n = 214) to 37% in the mid (2003–2006, n = 255) and to 44% in the most recent era (2007–2010, n = 208; P = 0.006 for years-by-era; P = 0.01 for era alone). C-peptide ≥0.3 ng/mL, indicative of islet graft function, was retained longer in the most recent era (P < 0.001). Reduction of HbA1c and resolution of severe hypoglycemia exhibited enduring long-term effects. Fasting blood glucose stabilization also showed improvements in the most recent era. There were also modest reductions in the occurrence of adverse events. The islet reinfusion rate was lower: 48% by 1 year in 2007–2010 vs. 60–65% in 1999–2006 (P < 0.01). Recipients that ever achieved insulin-independence experienced longer duration of islet graft function (P < 0.001). CONCLUSIONS The CITR shows improvement in primary efficacy and safety outcomes of islet transplantation in recipients who received transplants in 2007–2010 compared with those in 1999–2006, with fewer islet infusions and adverse events per recipient.